Vaccine Adjuvants Market, By Type (Mineral Salt-based Adjuvant, Tensoactive Adjuvants, Adjuvant Emulsions, Liposome Adjuvants, Carbohydrate Adjuvants, Bacteria-derived Adjuvants, Virus-like Particles (VLP), and Other Types), By Usage (Active Immunostimulants, Carriers, and Vehicle Adjuvants), By Disease Type (Infectious Disease and Cancer), By Application (Research Applications and Commercial Applications), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of World)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
An adjuvant is a vaccine component that boosts the immune response to the vaccine. An adjuvant is used to create a stronger immune response in people receiving the vaccine. In short, adjuvants help vaccines work better. Newer adjuvants have been developed to target specific components of the body’s immune response, so that protection against disease is stronger and lasts longer.
Market Dynamics:
Rise in prevalence of chronic/infectious diseases, increasing use of vaccine adjuvants, government initiatives or policies for immunization, outbreak of COVID-19 (pandemic), and increase in focus on the development of safe and effective vaccine are major factors expected to drive growth of the global vaccine adjuvants market over the forecast period.
For instance, in October 2022, MHRP and collaborators recently launched a Phase 1 trial that will evaluate safety, tolerability, and immunogenicity of varying doses of the Army’s ALFQ adjuvant in a candidate HIV vaccine to optimize adjuvant dosage.
Furthermore, in August 2021, Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation announced the rollout of its COVID-19 vaccine, MVC-COV1901. More than 600,000 people are anticipated to receive the Medigen vaccine this week.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook